



Better Training for Safer Food *Initiative*

Antimicrobial Resistance One Health approach

2017 EU AMR ACTION PLAN

BTSEF

This presentation is delivered under contract with the Consumers, Health, Agriculture and Food Executive Agency CHAFEA

(<http://ec.europa.eu/chafea>). The content of this presentation is the sole responsibility of AENOR and can in no way be taken to reflect the views of CHAFEA or any other body of the European Union. CHAFEA or any other body of the European Union will not be responsible under any circumstances for the contents of communication items prepared by the contractor.

Food safety

Malaga, Spain – 25-28 November 2019

Summary

1. Action Plan against the rising threats from AMR (2011-2016) and its evaluation
2. 2017 EU One Health Action Plan against AMR
 - Making the EU a best practice region
 - Boosting research, development and innovation
 - Shaping the global agenda



European
Commission



Directorate-General for
Health & Consumers

Communication from the Commission to the European Parliament and the Council

Action plan against the rising threats from Antimicrobial
Resistance

COM (2011) 748



Food safety

Action plan against the rising threats from AMR

COM (2011) 748 – 17 Nov 2011

- 5 year action plan
- Holistic approach
- 7 key areas
- 12 concrete actions

Conclusions

- The EC's AMR Action Plan has been successful at stimulating action to tackle AMR within MS, EU and globally.
- EU to continue to play a leading role (EU and globally) in addressing AMR as the threat continues to grow. It is important that the EU continues to play a leading role in addressing the problem.
- Action is still needed in all the sectors, but the EC's Action Plan has proven to be a good starting point and has laid a good basis for further global action.



A European One Health Action Plan against Antimicrobial Resistance (AMR)

2017 EU One Health Action Plan against AMR

The key objectives built on 3 pillars:

1. Making the EU a best practice region
2. Boosting research, development and innovation
3. Shaping the global agenda

The key objectives built on 3 pillars:



MAKING THE EU A BEST PRACTICE REGION ON AMR

- Better evidence and awareness
- Better coordination and implementation of EU rules
- Better prevention and control
- Better addressing the role of the environment
- A stronger partnership against AMR and better availability of antimicrobials



BOOSTING RESEARCH, DEVELOPMENT AND INNOVATION ON AMR

- New economic models & incentives
- Better detection and control measures
- New antimicrobials, rapid diagnostic tests, vaccines & alternative therapies
- AMR in the environment



SHAPING THE GLOBAL AGENDA ON AMR

- Stronger EU global presence, partnering
- Stronger bilateral partnership for stronger cooperation
- Cooperating with developing countries
- Developing a global research agenda



1. MAKING THE EU A BEST PRACTICE REGION

A. Better evidence and awareness of the challenges of AMR

- Strengthen One Health surveillance and reporting of AMR and antimicrobial use
- Benefit from the best evidence-based analysis and data
- Increase awareness and understanding

B. Better coordination and implementation of EU rules to tackle AMR

- Improve the coordination of Member States' One Health responses to AMR
- Better implementation of EU rules

C. Better prevention and control of AMR

- Strengthen infection prevention and control measures
- Promote the prudent use of antimicrobials

D. Better addressing the role of the environment

E. A stronger partnership against AMR and better availability of antimicrobials



2. BOOSTING RESEARCH, DEVELOPMENT AND INNOVATION

- A. Improve knowledge on detection, effective infection control and surveillance**
- B. Develop new therapeutics and alternatives, preventive vaccines, diagnostics**
- C. Develop new preventive vaccines, diagnostics**
- D. Develop novel diagnostics**
- E. Develop new economic models and incentives**
- F. Close knowledge gaps on AMR in the environment and on how to prevent transmission**



3. SHAPING THE GLOBAL AGENDA


- A. Stronger EU global presence**
- B. Stronger bilateral partnerships for stronger cooperation**
- C. Cooperating with developing countries**
- D. Developing a global research agenda**




Implementation of activities under pillar 1


- EU guidelines prudent use of antimicrobials in human (June 2017)
- One-Health AMR visits in Member States (June 2017)
- Second JIACRA report (July 2017)
- Inter-agency opinion on AMR indicators (September 2017)
- Joint action AMR and HCAI (September 2017)

EU-JAMRAI: THE PLACE TO BE TO TACKLE AMR!





44 participating partners



40 international stakeholders

- International organisations
- Civil society
- Industries
- Professionals of human and animal sectors


Bridge the gap between declarations and actions!

YESTERDAY

--- Strategic ---
DECLARATIONS
&

----- Strong -----
Political Will

EU-JAMRAI



TOMORROW

-- To implement --
CONCRETE ACTIONS at
Operational Level



**Reduction of
AMR Burden**



MAKE OUR DREAMS COME TRUE

EU-JAMRAI is a small step forward
DOWN THE ROAD of AMR reduction
contributing to:

1- Decrease consumption of antibiotics in humans and animals




2- Test wide implementation of programs to prevent HCAI

3- Analyse gaps in national action plans



4- Propose incentives for the development of antibiotics and diagnostic tools

5- Improve surveillance in human and animal



6- Increase awareness on AMR

AMR REDUCTION



Implementation of activities under pillar 1

- AMR Training (BTSF) for Competent Authorities (November 2017)
- AMR Training (BTSF) for Competent Authorities 3th countries (2018)
- European Antibiotic Awareness Day (November 2017)
- Audits of EU legislation on AMR monitoring in food/animals (ctd)
- Fact-finding missions prudent use (vet med) in Member States (ctd)
- Adoption of the new regulation VM and MF (January 2019)



Implementation of activities under pillar 2

- EU will make use of different funding instruments under current and future framework programmes for research and innovation.
- EU should make use all the latest developments in technology, data handling and IT.
- EU will invest in novel knowledge, tools and solutions for which we rely on research.



Investing in AMR R&D and innovation October

**October 2017 launch of Horizon 2020 work programme
for 2018-20**

https://ec.europa.eu/health/amr/projects_en

Call topics include:

- data mining to enable early detection of infectious diseases threats and resistant pathogens.
- development of new antimicrobials and alternatives to antimicrobials.
- collaboration with the Russian Federation on HIV and TB research.



European
Commission



Investing in AMR R&D and innovation





G20 on AMR

- The G20 (2017) called for a new international R&D Collaboration Hub on AMR to maximise the impact of existing and new antimicrobial basic and clinical research initiatives as well as product development.
- The Commission looks forward to further coordination and alignment of different initiatives in AMR research, which is in full alignment with the new European One Health Action Plan.
- It sees the JPIAMR is an important stakeholder in the hub, as it already gathers 26 countries funding AMR related research.



Implementation of activities under pillar 3

- Continue to actively contribute to the normative work of the WHO, the OIE, the FAO, and the Codex Alimentarius on the development of ambitious international frameworks and standards / norms / guidelines / methodologies related to AMR (Signature letter September 2017)
- SANTE participation in Codex Alimentarius Task force on AMR (2017, 2018, 2019)
- SANTE collaboration with FAO on a FAO manual on practical stepwise approaches to implementing prudent antimicrobial use guidelines (January 2018)



Implementation of activities under pillar 3

- Updated TATFAR work plan and deliverables (2018)
- AMR cooperation activities with India (VMP, November 2017) and South-American countries (ongoing)
- 4th tripartite meeting between PMDA, EMA, and FDA to discuss convergence on approaches for the evaluation of antibacterial drugs (2019)
- CVMP discussion on the needs to update existing VICH guidelines (2019)



This presentation is delivered under contract with the Consumers, Health, Agriculture and Food Executive Agency CHAFEA (<http://ec.europa.eu/chafea>). The content of this presentation is the sole responsibility of AENOR and can in no way be taken to reflect the views of CHAFEA or any other body of the European Union. CHAFEA or any other body of the European Union will not be responsible under any circumstances for the contents of communication items prepared by the contractor.

AENOR INTERNACIONAL

6, Genova street. 28004. Madrid, SPAIN

Tel: +34 91 432 61 25

Mail: 20169607_amr@aenor.com

www.btsf-aenor.com



Better Training for Safer Food BTSF

• *European Commission
Consumers, Health, Agriculture and Food Executive Agency
DRB A3/042
L-2920 Luxembourg*